161 related articles for article (PubMed ID: 23877991)
61. Human insulin does not increase bladder cancer risk.
Tseng CH
PLoS One; 2014; 9(1):e86517. PubMed ID: 24466131
[TBL] [Abstract][Full Text] [Related]
62. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
63. Lower rate of cardiovascular complications in patients on bolus insulin analogues: a retrospective population-based cohort study.
Cammarota S; Falconio LM; Bruzzese D; Catapano AL; Casula M; Citarella A; De Luca L; Flacco ME; Manzoli L; Masulli M; Menditto E; Mezzetti A; Riegler S; Novellino E; Riccardi G
PLoS One; 2013; 8(11):e79762. PubMed ID: 24244557
[TBL] [Abstract][Full Text] [Related]
64. Charitable medication distribution improves care for uninsured patients with diabetes.
Hughes J; Sparkman A; Smith P; McCormack T; Campbell T; Blackburn H
Am J Manag Care; 2023 Nov; 29(11):573-575. PubMed ID: 37948644
[TBL] [Abstract][Full Text] [Related]
65. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
Tang X; Yang L; He Z; Liu J
PLoS One; 2012; 7(12):e51814. PubMed ID: 23284776
[TBL] [Abstract][Full Text] [Related]
66. Cancer specific mortality in insulin-treated type 2 diabetes patients.
Ioacara S; Guja C; Ionescu-Tirgoviste C; Fica S; Roden M
PLoS One; 2014; 9(3):e93132. PubMed ID: 24667573
[TBL] [Abstract][Full Text] [Related]
67. Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study.
Alkabbani W; Maxwell CJ; Marrie RA; Tyas SL; Lega IC; Gamble JM
Diabetes Care; 2023 Aug; 46(8):1492-1500. PubMed ID: 37315211
[TBL] [Abstract][Full Text] [Related]
68. A Salutary Tale-Glargine insulin and cancer risk.
Boyle P
Ecancermedicalscience; 2009; 3():ed5. PubMed ID: 24966880
[No Abstract] [Full Text] [Related]
69. Weekly Insulin Becoming a Reality.
Skyler JS
Diabetes Care; 2021 Jul; 44(7):1459-1461. PubMed ID: 34155035
[No Abstract] [Full Text] [Related]
70. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
71. Acute kidney injury in statin initiators.
Layton JB; Brookhart MA; Jonsson Funk M; Simpson RJ; Pate V; Stürmer T; Kshirsagar AV
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1061-70. PubMed ID: 23960024
[TBL] [Abstract][Full Text] [Related]
72. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
73. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
74. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
75. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.
Wu JW; Filion KB; Azoulay L; Doll MK; Suissa S
Diabetes Care; 2016 Mar; 39(3):486-94. PubMed ID: 26740633
[TBL] [Abstract][Full Text] [Related]
76. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin.
Lim S; Stember KG; He W; Bianca PC; Yelibi C; Marquis A; Stürmer T; Buse JB; Meigs JB
PLoS One; 2014; 9(10):e109433. PubMed ID: 25329887
[TBL] [Abstract][Full Text] [Related]
77. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.
Karlstad O; Starup-Linde J; Vestergaard P; Hjellvik V; Bazelier MT; Schmidt MK; Andersen M; Auvinen A; Haukka J; Furu K; de Vries F; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):333-48. PubMed ID: 24215311
[TBL] [Abstract][Full Text] [Related]
78. Cancer biology in diabetes update: Focusing on antidiabetic drugs.
Kawakita E; Kanasaki K
J Diabetes Investig; 2024 May; 15(5):525-540. PubMed ID: 38456597
[TBL] [Abstract][Full Text] [Related]
79. A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments.
Winterstein AG; Ehrenstein V; Brown JS; Stürmer T; Smith MY
Diabetes Care; 2023 Aug; 46(8):1448-1454. PubMed ID: 37471605
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
